Physician profile
Michael J Doyle
NPI 1497856959
$1,114.40
in general payments reported to CMS, 2019-2025
14 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2021: $107 · 2022: $218 · 2023: $168 · 2024: $376 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629 · Education: $37.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.69 |
| Education | $37.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $419.71 | 2023-2025 | Pivox Oblique Lateral Spinal System, Endurant Iis, Anteralign Spinal System With Titan Nanolock Surface Technology |
| Cumberland Pharmaceuticals, INC. | $161.62 | 2022 | |
| Medtronic USA, INC. | $123.51 | 2019 | |
| Si-Bone, INC. | $97.70 | 2021-2024 | |
| Abbott Laboratories | $76.71 | 2022-2023 | Proclaim |
| Orthofix Medical, INC. | $52.89 | 2021 | |
| Amgen INC. | $51.60 | 2023-2024 | Prolia, Evenity |
| Vertex Pharmaceuticals Incorporated | $41.89 | 2024-2025 | |
| Pfizer INC. | $16.85 | 2024 | |
| Nestle Healthcare Nutrition INC. | $16.65 | 2022 | |
| Abbvie INC. | $15.15 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.05 | 2023 | Zilretta, Iovera, Exparel |
| Nevro Corp. | $13.16 | 2023 | Senza |
| Zimmer Biomet Holdings, INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.